Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Pinealon 20mg Dosage Chart & Cycle Guide - Dosage Peptide

Pinealon (20mg Vial) Dosage Protocol Khavinson brain/CNS short-peptide bioregulator (EDR) — research-only; documented human use is oral, not approved. Mix & measure Pinealon · 20 mg Pre-filled with this protocol’s recommended BAC water and documented starting

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Pinealon (20mg Vial) Dosage Protocol

Khavinson brain/CNS short-peptide bioregulator (EDR) — research-only; documented human use is oral, not approved.

Mix & measure Pinealon · 20 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration ~6.67 mg/mL (6,667 mcg/mL).

Typical daily range: 200–500 mcg once daily, raised gradually over a 12-week course. This subcutaneous schedule is educational only — not established in human trials.

Easy measuring: At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe. Compute units as dose (mcg) ÷ 66.7 — e.g., 200 mcg ≈ 3 units, 500 mcg ≈ 7.5 units.

Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Matrixyl 3000 — frequently asked questions

Matrixyl 3000 is a topical cosmetic peptide applied to the skin as part of a serum or cream — not injected or taken by mouth. It is blended into a water-based base at a chosen percentage and applied to clean skin. Cosmetic formulations commonly use roughly 3 to 10 percent. Higher is not necessarily better and can affect texture, stability and skin tolerability. The strength shown on this page is a formulation reference, not a dose to inject. No. As a topical peptide, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — it is dissolved into a serum or cream base and applied to the skin. Keep the raw powder sealed, cool, dry and away from light. A finished water-based peptide serum is best refrigerated and used within a few weeks, since peptides in solution degrade over time. No. Matrixyl 3000 is a cosmetic-grade ingredient for topical formulation and research, not an approved medicine; the evidence supports only modest topical, cosmetic effects. Everything here is research and educational information, not medical advice.

Source: dosagepeptide.com ↗
02Tesofensine — frequently asked questions

Tesofensine is taken by mouth as one or more capsules once daily, swallowed whole with or without food. There is no mixing, reconstitution, or injection — it is an oral small-molecule compound, not an injectable peptide. No. Because Tesofensine is an oral capsule, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — you simply take the capsule(s) by mouth. Each capsule is a fixed strength, so a target dose is reached by taking the matching number of capsules at that strength. The dosing table on this page lists the reference dose for each step of a documented research schedule — match your capsule strength to it rather than assuming a fixed number. Keep the capsules in their original sealed container at controlled room temperature, dry and away from heat, light and moisture, and follow the specific storage guidance supplied with your product. No refrigeration or reconstitution is required. The main practical difference is the route of administration: Tesofensine is swallowed as a capsule, so there is no reconstitution, bacteriostatic water, or sterile injection technique involved. Its specific mechanism of action and the research behind it are described in the "How This Works" section on this page. No. Research-grade Tesofensine is supplied strictly for laboratory and research purposes and is not an approved medicine for human use — regardless of whether an approved pharmaceutical product containing this ingredient exists. Everything here is research information, not medical advice; consult a licensed healthcare professional and the approved product labeling before any use.

Source: dosagepeptide.com ↗
03Argireline — frequently asked questions

Argireline is a topical cosmetic peptide applied to the skin as part of a serum or cream — not injected or taken by mouth. It is blended into a water-based base at a chosen percentage and applied to clean skin. Cosmetic formulations commonly use roughly 3 to 10 percent. Higher is not necessarily better and can affect texture, stability and skin tolerability. The strength shown on this page is a formulation reference, not a dose to inject. No. As a topical peptide, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — it is dissolved into a serum or cream base and applied to the skin. Keep the raw powder sealed, cool, dry and away from light. A finished water-based peptide serum is best refrigerated and used within a few weeks, since peptides in solution degrade over time. No. Argireline is a cosmetic-grade ingredient for topical formulation and research, not an approved medicine; the evidence supports only modest topical, cosmetic effects. Everything here is research and educational information, not medical advice.

Source: dosagepeptide.com ↗
04Dihexa — frequently asked questions

Dihexa is taken by mouth as one or more capsules once daily, swallowed whole with or without food. There is no mixing, reconstitution, or injection — it is an oral small-molecule compound, not an injectable peptide. No. Because Dihexa is an oral capsule, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — you simply take the capsule(s) by mouth. Each capsule is a fixed strength, so a target dose is reached by taking the matching number of capsules at that strength. The dosing table on this page lists the reference dose for each step of a documented research schedule — match your capsule strength to it rather than assuming a fixed number. Keep the capsules in their original sealed container at controlled room temperature, dry and away from heat, light and moisture, and follow the specific storage guidance supplied with your product. No refrigeration or reconstitution is required. The main practical difference is the route of administration: Dihexa is swallowed as a capsule, so there is no reconstitution, bacteriostatic water, or sterile injection technique involved. Its specific mechanism of action and the research behind it are described in the "How This Works" section on this page. No. Research-grade Dihexa is supplied strictly for laboratory and research purposes and is not an approved medicine for human use — regardless of whether an approved pharmaceutical product containing this ingredient exists. Everything here is research information, not medical advice; consult a licensed healthcare professional and the approved product labeling before any use.

Source: dosagepeptide.com ↗
05Enclomiphene — frequently asked questions

Enclomiphene is taken by mouth as one or more capsules once daily, swallowed whole with or without food. There is no mixing, reconstitution, or injection — it is an oral small-molecule compound, not an injectable peptide. No. Because Enclomiphene is an oral capsule, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — you simply take the capsule(s) by mouth. Each capsule is a fixed strength, so a target dose is reached by taking the matching number of capsules at that strength. The dosing table on this page lists the reference dose for each step of a documented research schedule — match your capsule strength to it rather than assuming a fixed number. Keep the capsules in their original sealed container at controlled room temperature, dry and away from heat, light and moisture, and follow the specific storage guidance supplied with your product. No refrigeration or reconstitution is required. The main practical difference is the route of administration: Enclomiphene is swallowed as a capsule, so there is no reconstitution, bacteriostatic water, or sterile injection technique involved. Its specific mechanism of action and the research behind it are described in the "How This Works" section on this page. No. Research-grade Enclomiphene is supplied strictly for laboratory and research purposes and is not an approved medicine for human use — regardless of whether an approved pharmaceutical product containing this ingredient exists. Everything here is research information, not medical advice; consult a licensed healthcare professional and the approved product labeling before any use.

Source: dosagepeptide.com ↗
comparison

Practical implications of the comparison

The productive way to use the Semax comparison is as a modeling boundary, not a prescription. The Semax literature establishes the concentration range at which this chemical family has been…

Source: dosagepeptide.com
comparison

Why the IFG Versus IGT Distinction Matters for an Amylin Agent

The two main prediabetes phenotypes are not interchangeable, and the distinction is directly relevant to how an amylin analogue might be expected to behave. Isolated impaired fasting glucos…

Source: dosagepeptide.com
Research context

Read sources and limitations before applying a claim.

What Is the Current Evidence Level for Prostamax?

Stated precisely, with no inflation in either direction: FDA-approved for any indication No. Prostamax is not approved by FDA for any indication. Approved by any other regulator No approval located in any jurisdiction. Investigational (in registered trials) No. Zero records on ClinicalTrials.gov. None located. Peer-reviewed human studies of any design Human administration described anywhere Yes — but only in the applicant’s own examples inside a lapsed patent (35 + 19 men, IM, 0.01–100 mcg/kg, 10–40 days). Not peer-reviewed, not registered, not appraisable. In vivo animal studies Yes — two rat studies (IM) from one Tomsk group in a journal not indexed in MEDLINE, single dose level each, contradicting each other a thousand-fold on dose. Plus patent-described rat models. Dose-ranging study (any species) Ex vivo / organotypic culture Yes — rat prostate explants at 0.05 ng/mL[6] In vitro (human cells) Yes — chromatin studies in donor lymphocytes[3] Peer-reviewed toxicology None located. Toxicology exists only as the applicant’s account inside the patent. Pharmacokinetics (any species) The honest one-line summary: Prostamax has a small in vitro literature, a two-study non-indexed animal literature that contradicts itself on dose, and a human record that exists only inside a lapsed patent written by the people who wanted the patent. Any characterisation of it as “clinically studied” is false. Any characterisation drawing on Prostatilen’s trial data is describing a different substance. And any characterisation claiming there is no animal or human record at all is also false — which matters, because that particular overstatement is the one most likely to make a reader stop checking, and a reader who stops checking is exactly who a bad protocol needs. It is equally important not to overcorrect in the other direction. This is not a fabricated compound. It has an NLM MeSH identity, a fully characterised sequence and molecular weight, a patent from a real research institute containing real analytical data, a real if small primary literature, and a mechanistic hypothesis with genuine supporting work at the family level. The correct statement is not “Prostamax is fake” but “Prostamax is real, early-stage, and nowhere near the evidentiary maturity implied by the protocols written for it.”

Source: dosagepeptide.com ↗

Human evidence: the cagrilintide component

Cagrilintide has robust human weight data but no dedicated human liver-histology data. In a phase 2 dose-finding trial in adults with overweight or obesity, once-weekly cagrilintide monotherapy across doses from 0.3 mg to 4.5 mg produced dose-dependent weight loss, reaching roughly 10.8% at the top dose over 26 weeks versus about 3.0% with placebo.[5] Because weight loss of that magnitude is expected to reduce hepatic fat, the drug is a plausible liver-relevant agent — but that inference is not a substitute for a MASH trial, and none has been reported for cagrilintide alone.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Why do sources disagree so much on Vilon dosage?

Because there is no authoritative source to anchor to. With no controlled dose-ranging study, every figure is either an experimental quantity from a narrow literature or a supplier convention copied across the bioregulator family. Different writers pick different anchors, so the numbers diverge. The honest reading is that the disagreement reflects an absence of evidence, not competing bodies of evidence.

Source: dosagepeptide.com ↗
Storage reference

Chemistry, stability, and modified forms

The chemical simplicity of DSIP hides some real subtlety that matters for interpreting the research. The single aspartate residue in the sequence is prone to isomerization: the biologically active molecule is the alpha-aspartyl form, whereas the beta-aspartyl isomer that can form spontaneously is largely inactive, a distinction the Basel group established when they synthesized and tested the peptide.[2] This means a nominally “DSIP” sample can degrade toward an inactive species over time and under adverse storage conditions — a genuine complication for reproducibility, because two laboratories nominally studying the same peptide might be studying subtly different mixtures of active and inactive forms. Researchers also described modified variants, most notably a phosphorylated form of DSIP (often abbreviated DSIP-P), phosphorylated on the serine residue, which was reported to have somewhat different properties and stability from the unphosphorylated parent. The existence of such naturally occurring modified forms complicated efforts to define a single “the” DSIP and to reconcile discordant results across studies.[5] When a research literature cannot fully agree on which molecular species is doing what, clean replication becomes correspondingly harder.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →